JAN 15, 2016 04:19 AM PST

New Blood Test Detects Melanoma's Spread

WRITTEN BY: Xuan Pham
Metastasis is one of the biggest challenges facing current available cancer treatments. It is this unpredictable progression of cancer that makes melanoma the most deadly form of skin cancers. But results from a new study may help doctors track the cancer’s spread by measuring levels of DNA from circulating tumor cells.
 
Circulating tumor DNA can help detect cancer's presence.

Circulating tumor DNA (ctDNA), also known as cell-free tumor DNA, is genetic material that’s freely floating in the bloodstream of cancer patients. The source of ctDNA is the tumor, where dead tumor cells break open and release the tumor DNA into the patient’s blood. ctDNA represents a non-invasive cancer biomarker that can indicate the presence of disease. And because detection requires only a blood sample, the technique of using ctDNA for cancer diagnosis is often called “liquid biopsy.”
 
The researchers proposed that ctDNA could provide an accurate way to track the progression of metastatic melanoma. Since the ctDNA is specific to the melanoma tumor, this new test could provide better diagnostic accuracy than traditional tests that measure an enzyme called lactate dehydrogenase (LDH). Though LDH levels do rise in presence of aggressive tumors, it is also affected by other health conditions, which could convolute the accuracy of the LDH screen.
 
In 31 patients who had advanced metastatic melanomas, researchers found that ctDNA levels were more predictive of the disease progression than levels of LDH. ctDNA levels were elevated in 80% of the patients, as compared to LDH levels that were elevated in only 30% of patients.
 
ctDNA levels were also better at predicting cancer recurrence (85% of patients) compared to LDH levels (54% of patients). Recurrence rates were confirmed by X-ray or CT scans.
 
Overall, the ctDNA screen had higher sensitivity than the LDH screen at detecting the spread of melanoma. 
 
"Our study results show that circulating tumor DNA is a superior blood test for evaluating and tracking progression of metastatic melanoma," said David Polsky, senior investigator from NYU Langone Medical Center in New York City.
 
While these results are promising, it is important to note that the study was done on a very small number of patients. It will be prudent for the scientists to expand on these preliminary results in a larger cohort of patients and controls. Larger trials should demonstrate with higher confidence the potential use of ctDNA as a biomarker for monitoring melanoma disease activity. 
 

Additional source: Medicine Net
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JUN 12, 2018
Cell & Molecular Biology
JUN 12, 2018
Loss of Brain Lesions may Indicate Worsening MS
New research could help doctors determine how severe a case of multiple sclerosis will become....
JUL 01, 2018
Videos
JUL 01, 2018
Growing Patient Cells on a Chip for Personalized Drug Screens
This work could help eliminate animal models, and tailor medicine to the patient....
JUL 07, 2018
Cardiology
JUL 07, 2018
Hybrid Imaging of the Heart Predicts Heart Attack Risk
The combination of two different types of imaging seems to be the most accurate way to predict heart attacks. Based on studies from the University Hospital...
AUG 16, 2018
Clinical & Molecular DX
AUG 16, 2018
Nanotech patch makes light-up medical tests 100x brighter
Researchers have developed a high-tech fix that uses metal nanostructures to increase the fluorescence intensity by 100 times in diagnostic tests. It&rsquo...
AUG 16, 2018
Clinical & Molecular DX
AUG 16, 2018
Bubbles and a blood test could detect brain tumors
Researchers have developed a proof-of-concept technique that allows them to detect brain tumor biomarkers with a simple blood test, rather than a complicat...
OCT 17, 2018
Cell & Molecular Biology
OCT 17, 2018
Saving Patients From Unnecessary Chemotherapy with a Blood Test
Often, cancer patients get chemotherapy after surgery to ensure that their cancer will not come back; for many it's not needed....
Loading Comments...